About Sphingosine 1-phosphate receptor 3
Sphingosine 1-phosphate receptor 3 (S1PR3) is a protein
from Homo sapiens identified by UniProt accession
Q99500, 378 residues long.
MolForge cross-references it against 0 known binders and
323 disease associations.
Target properties
| Protein name | Sphingosine 1-phosphate receptor 3 |
| UniProt accession | Q99500 |
| Gene | S1PR3 |
| Organism | Homo sapiens |
| Length | 378 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (323)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.60
- relapsing-remitting multiple sclerosis · score 0.59
- monocyte count · score 0.53
- monocyte percentage of leukocytes · score 0.49
- leukocyte count · score 0.43
- platelet count · score 0.43
- HbA1c measurement · score 0.42
- granulocyte percentage of myeloid white cells · score 0.42
- Red cell distribution width · score 0.42
- lymphocyte count · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q99500-F1 | alphafold | PREDICTED | 79.31 | — |
Amino-acid sequence (378 residues)
MATALPPRLQ PVRGNETLRE HYQYVGKLAG RLKEASEGST LTTVLFLVIC SFIVLENLMV LIAIWKNNKF HNRMYFFIGN LALCDLLAGI AYKVNILMSG KKTFSLSPTV WFLREGSMFV ALGASTCSLL AIAIERHLTM IKMRPYDANK RHRVFLLIGM CWLIAFTLGA LPILGWNCLH NLPDCSTILP LYSKKYIAFC ISIFTAILVT IVILYARIYF LVKSSSRKVA NHNNSERSMA LLRTVVIVVS VFIACWSPLF ILFLIDVACR VQACPILFKA QWFIVLAVLN SAMNPVIYTL ASKEMRRAFF RLVCNCLVRG RGARASPIQP ALDPSRSKSS SSNNSSHSPK VKEDLPHTAP SSCIMDKNAA LQNGIFCN
Explore Sphingosine 1-phosphate receptor 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets